PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28356941-11 2017 ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM. Aspirin 0-3 BCL2 apoptosis regulator Homo sapiens 126-131 33427041-9 2021 COX-independent mechanisms of anticancer effects of aspirin include down-regulation of nuclear factor kappa B activity and Akt activation, modulation of Bcl-2 and Bax family proteins, suppression of vascular endothelial growth factor, induction of apoptosis, disruption of DNA repair mechanisms, and induction of spermidine/spermine N1-acetyltransferase that modulates polyamine catabolism. Aspirin 52-59 BCL2 apoptosis regulator Homo sapiens 153-158 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 55-72 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 128-133 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 55-72 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 74-79 29805582-6 2018 Aspirin also significantly decreased the expression of B-cell lymphoma 2 (Bcl-2) and caspase-3, and increased the expression of Bcl-2-associated X protein, suggesting that aspirin induced apoptosis through the intrinsic apoptotic pathway. Aspirin 172-179 BCL2 apoptosis regulator Homo sapiens 128-133 29349624-3 2018 Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis. Aspirin 40-47 BCL2 apoptosis regulator Homo sapiens 106-111 29286113-0 2018 Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway. Aspirin 45-52 BCL2 apoptosis regulator Homo sapiens 115-120 29286113-15 2018 The synergistic effect of nutlin-3 in aspirin antitumor therapy contributed to diminishing the dose of aspirin required and decreased the occurrence of adverse drug events in HCC through targeting the Bcl-2/Bax signaling pathway. Aspirin 38-45 BCL2 apoptosis regulator Homo sapiens 201-206 28356941-0 2017 Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 95-100 32000660-8 2020 The expression of Bax/Bcl2 increased after treatment indicates that aspirin can induce apoptosis of PIK3CA-mutant CRC cells. Aspirin 68-75 BCL2 apoptosis regulator Homo sapiens 22-26 31905343-6 2020 The combined treatment of aspirin and cisplatin suppressed the expression of the anti-apoptotic protein Bcl-2 and the EMT-related proteins, up-regulated the levels of the cleaved PARP and Bax, and blocked the PI3K/AKT and RAF-MEK-ERK signaling pathway. Aspirin 26-33 BCL2 apoptosis regulator Homo sapiens 104-109 30944660-0 2019 Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 87-92 30144594-9 2018 mRNA expression analysis displayed a marked effect of ASA in reducing VEGF, VEGFR-1, HIF-1alpha, RAS, mitogen-activated protein kinase kinase, AKT, and BCL-2, as well a combined anticancer effect of ASA together with TMZ, BEV, and SUN. Aspirin 54-57 BCL2 apoptosis regulator Homo sapiens 152-157 29408091-6 2018 Aspirin disrupted the interaction between Bcl-2 and Beclin-1. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 42-47 26711147-5 2016 In addition, ASA could led to a loss in the mitochondrial out membrane potential, up-regulate p53, phosphorylated p53 and Bax, down-regulate Bcl-2, release cytochrome c from the mitochondria to the cytoplasm, and activate caspase-9 and caspase-3 in A549 cells, which revealed that ASA could also induce apoptosis through the mitochondria mediated pathway. Aspirin 13-16 BCL2 apoptosis regulator Homo sapiens 141-146 24766194-0 2014 Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 101-106 25857363-4 2015 HS alone and ASA + HS caused a major up-regulation of HSP70 mRNA in the first 2 h, while HSP70 protein increased gradually and was especially abundant from 2 h to 24 h. Regarding Bcl-2, all treatments rendered similar results: gene expression was down-regulated in the first 2 h, after which there was protein elevation (12-48 h after HS). Aspirin 13-16 BCL2 apoptosis regulator Homo sapiens 179-184 25857363-6 2015 In conclusion, 0.4 mM ASA + HS does not act as a co-inducer of HSP70 in HepG2 cells, but promotes Bcl-2 protein expression during prolonged treatment. Aspirin 22-25 BCL2 apoptosis regulator Homo sapiens 98-103 26056043-0 2015 Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Aspirin 24-31 BCL2 apoptosis regulator Homo sapiens 154-159 26056043-7 2015 Remarkably, metformin combined with aspirin significantly downregulated the anti-apoptotic proteins Mcl-1 and Bcl-2, and upregulated the pro-apoptotic proteins Bim and Puma, as well as interrupted their interactions. Aspirin 36-43 BCL2 apoptosis regulator Homo sapiens 110-115 26056043-10 2015 Taken together, the combination of metformin and aspirin significantly inhibited pancreatic cancer cell growth in vitro and in vivo by regulating the pro- and anti-apoptotic Bcl-2 family members, supporting the continued investigation of this two drug combination as chemopreventive or chemotherapeutic agents for pancreatic cancer. Aspirin 49-56 BCL2 apoptosis regulator Homo sapiens 174-179 24766194-8 2014 The myeloma cells exposed to ASA treatment displayed concentration-dependent apoptosis, which was closely associated with activation of caspases, upregulation of Bax, and downregulation of Bcl-2 and VEGF. Aspirin 29-32 BCL2 apoptosis regulator Homo sapiens 189-194 24113271-0 2013 Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 16-21 24113271-1 2013 Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin 77-84 BCL2 apoptosis regulator Homo sapiens 21-38 24113271-1 2013 Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin 77-84 BCL2 apoptosis regulator Homo sapiens 40-45 24113271-2 2013 Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 49-54 24113271-2 2013 Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 107-112 24113271-4 2013 Bcl-2 knockdown using small interfering RNA (siRNA) delayed apoptotic cell death, which correlated with increased proliferation following aspirin exposure. Aspirin 138-145 BCL2 apoptosis regulator Homo sapiens 0-5 24113271-5 2013 In contrast, Bcl-2 overexpression enhanced the onset of aspirin-induced apoptosis, which was also associated with a significant increase in Bcl-2 phosphorylation in the nucleus. Aspirin 56-63 BCL2 apoptosis regulator Homo sapiens 13-18 24113271-6 2013 Therefore, this study may provide novel insight into the molecular mechanism of aspirin, particularly its anticancer effects in Bcl-2- and estrogen receptor-positive breast cancer cells. Aspirin 80-87 BCL2 apoptosis regulator Homo sapiens 128-133 22179060-5 2012 We found that treatment with aspirin inhibited cell growth and induced apoptosis involving both extrinsic and intrinsic pathways as measured by DNA ladder formation, alteration in the Bax/Bcl-2 ratio, activation of the caspase activities and related protein expressions. Aspirin 41-48 BCL2 apoptosis regulator Homo sapiens 224-229 23799623-8 2013 The antagonism of MTX efficacy caused by ASA was accompanied by altered expression of caspase-3, Bcl-2 and FAS but not dihydrofolate reductase (DHFR). Aspirin 41-44 BCL2 apoptosis regulator Homo sapiens 97-102 23799623-9 2013 This suggests that the alteration of caspase-3, Bcl-2 and FAS was involved in the antagonism between ASA and MTX. Aspirin 101-104 BCL2 apoptosis regulator Homo sapiens 48-53 23317278-6 2012 In addition, the combination of exemestane and aspirin exhibited a synergistic inhibition of cell proliferation, significantly arrested the cell cycle in the G0/G1 phase and produced a stronger inhibitory effect on COX-1 and Bcl-2 expression than control or individual drug treatment. Aspirin 47-54 BCL2 apoptosis regulator Homo sapiens 225-230 21361874-8 2011 The bcl-2, p53 and cox-2 genes in both cell lines treated with ASA seem to exhibit different patterns of expression. Aspirin 63-66 BCL2 apoptosis regulator Homo sapiens 4-9 21361874-4 2011 The mechanism of action of different concentrations of ASA were compared in K562 (non-MDR) and Lucena (MDR) cells by analysing cell viability, apoptosis and necrosis, intracellular ROS (reactive oxygen species) formation and bcl-2, p53 and cox-2 gene expression. Aspirin 55-58 BCL2 apoptosis regulator Homo sapiens 225-230 19936928-7 2010 We studied the regulation of Bcl-2 family members in aspirin-induced apoptosis. Aspirin 53-60 BCL2 apoptosis regulator Homo sapiens 29-34 19424877-8 2010 To further investigate the underlying mechanism by which aspirin exerts its apoptosis effects, we studied the ErbB2 downstream cell survival signaling pathways and the expression of anti-apoptosis gene Bcl-2. Aspirin 57-64 BCL2 apoptosis regulator Homo sapiens 202-207 19595669-5 2009 Moreover, the expression of STAT3 target genes such as Cyclin D1, XIAP, and Bcl-2 that are essential for cell growth and survival was apparently attenuated after aspirin treatment. Aspirin 162-169 BCL2 apoptosis regulator Homo sapiens 76-81 19966835-10 2010 Aspirin inhibits GSK-3beta activation and suppresses the expression of its downstream gene products (cyclin D1 and Bcl-2), which are implicated in proliferation, survival and chemoresistance of pancreatic cancer. Aspirin 0-7 BCL2 apoptosis regulator Homo sapiens 115-120 18636671-10 2008 After treatment with aspirin, SW480 cells displayed typically morphological features of apoptosis and necrosis under TEM, and increased the Bcl-2 expression in cells, but the expression of Bax was down regulated. Aspirin 21-28 BCL2 apoptosis regulator Homo sapiens 140-145 15546508-5 2004 Both ASA and indomethacin reduced the protein levels of Bcl-2 and Bcl-xl, but upregulated those of Bax and Bcl-xs. Aspirin 5-8 BCL2 apoptosis regulator Homo sapiens 56-61 15976387-1 2005 This study was undertaken to determine whether the Bcl-2 family proteins and Smac are regulators of aspirin-mediated apoptosis in a gastric mucosal cell line known as AGS cells. Aspirin 100-107 BCL2 apoptosis regulator Homo sapiens 51-56 15976387-5 2005 ASA downregulated Bcl-2 protein expression and induced Bax translocation into the mitochondria and cleavage of Bid. Aspirin 0-3 BCL2 apoptosis regulator Homo sapiens 18-23 16199534-0 2005 Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. Aspirin 16-36 BCL2 apoptosis regulator Homo sapiens 139-144 16199534-6 2005 Most interestingly, at least 12 h of pretreatment with ASA was prerequisite for promoting TRAIL-induced apoptosis and was related to down-regulation of BCL-2. Aspirin 55-58 BCL2 apoptosis regulator Homo sapiens 152-157 16199534-7 2005 Biochemical analysis revealed that ASA inhibited NF-kappaB activity, which is known to regulate BCL-2 gene expression, by dephosphorylating IkappaB-alpha and inhibiting IKKbeta activity but not by affecting the HER-2/neu phosphatidylinositol 3-kinase-Akt signal pathway. Aspirin 35-38 BCL2 apoptosis regulator Homo sapiens 96-101 16199534-8 2005 Overexpression of BCL-2 suppressed the promotive effect of ASA on TRAIL-induced apoptosis and changes in mitochondrial membrane potential. Aspirin 59-62 BCL2 apoptosis regulator Homo sapiens 18-23 16199534-9 2005 Taken together, our studies suggested that ASA-promoted TRAIL cytotoxicity is mediated through down-regulating BCL-2 and by decreasing mitochondrial membrane potential. Aspirin 43-46 BCL2 apoptosis regulator Homo sapiens 111-116 12423325-11 2002 After treatment with ASA, down-regulation of Bcl2 and CD44v6 expression and up-regulation of nm23 expression were observed in SW480 cells. Aspirin 21-24 BCL2 apoptosis regulator Homo sapiens 45-49 12490308-0 2003 The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Aspirin 26-33 BCL2 apoptosis regulator Homo sapiens 87-92 12490308-11 2003 We have demonstrated that combined treatment of aspirin and radiation induces the antitumor effect mediated by bcl-2 and caspase-3 pathway in cervical cancer cells. Aspirin 48-55 BCL2 apoptosis regulator Homo sapiens 111-116 14636445-5 2003 The expression of Bcl-2 in SMMC-7721 cells treated by 3 mmol/L or 10 mmol/L aspirin decreased markedly, but no effect on Bax. Aspirin 76-83 BCL2 apoptosis regulator Homo sapiens 18-23 14636445-6 2003 CONCLUSION: The cooperative anti-tumor effect of aspirin and TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin Aspirin 49-56 BCL2 apoptosis regulator Homo sapiens 121-126 14636445-6 2003 CONCLUSION: The cooperative anti-tumor effect of aspirin and TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin Aspirin 130-137 BCL2 apoptosis regulator Homo sapiens 121-126 12423325-14 2002 Down-regulation of Bcl2 expression might represent a potential mechanism by which ASA induces apoptosis in this COX-2 negative colon cancer cell line. Aspirin 82-85 BCL2 apoptosis regulator Homo sapiens 19-23 11986787-7 2002 Furthermore, aspirin treatment is associated with an increase in bcl-2 expression, which persists in the presence of the anticancer drugs. Aspirin 13-20 BCL2 apoptosis regulator Homo sapiens 65-70 10868686-7 2000 Down-regulation of bcl-2 by aspirin was found in the two cell lines tested. Aspirin 28-35 BCL2 apoptosis regulator Homo sapiens 19-24 11239649-10 2001 Control cells and cells treated with the lowest concentration of ASA exhibited 2% apoptosis and more than 60% of the population expressed bcl-2. Aspirin 65-68 BCL2 apoptosis regulator Homo sapiens 138-143